glp-1 liver toxicity Why are agonists being used to treat patients with nonalcoholic fatty disease? glp 1 agonist liver disease

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

Frohman, Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog, J

27 Effects of GLP-1 RAs on Cardiac Structure and Function GLP-1 RAs have garnered significant interest due to their potential benefits beyond glycaemic control, including their effects on cardiac function

By the late 1980s, it was clear that therapeutically using GLP-1 would require either modifying the molecule to last longer or finding another way to keep levels high

We found that the receptor doesnt just signal at the cell surface, it moves inside the cell to form a specialised hub at ER contact sites